Researcher
Arnaud Marchand
- Disciplines:Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences, Bioinformatics and computational biology
Affiliations
- Medicinal Chemistry (Rega Institute) (Division)
Member
From1 Oct 2000 → 30 Sep 2002
Publications
11 - 20 of 22
- Analysis of the mode of action of a Pseudomonas aeruginosa anti-persister compound(2015)
Authors: Valerie Defraine, Veerle Liebens, Toon Swings, Arnaud Marchand, Patrick Chaltin, Maarten Fauvart
Pages: 137 - 143 - H1PVAT is a novel and potent early-stage inhibitor of poliovirus replication that targets VP1(2014)
Authors: Aloys Tijsma, Hendrik Jan Thibaut, Armando De Palma, Mohamed Koukni, Arnaud Marchand, Patrick Chaltin, Johan Neyts, Pieter Leyssen
Pages: 1 - 9 - Identification and characterization of an anti-pseudomonal dichlorocarbazol derivative displaying anti-biofilm activity(2014)
Authors: Veerle Liebens, Evelien Gerits, Wouter Knapen, Toon Swings, Hans Steenackers, Stijn Robijns, Arnaud Marchand, Patrick Chaltin, Katrijn De Brucker, Karin Thevissen, et al.
Pages: 5404 - 5408 - LEDGINs, non-catalytic site inhibitors of HIV-1 integrase: a patent review (2006 - 2014)(2014)
Authors: Jonas Demeulemeester, Patrick Chaltin, Arnaud Marchand, Marc De Maeyer, Zeger Debyser, Frauke Christ
Pages: 609 - 632 - Repurposing as a means to increase the activity of amphotericin B and caspofungin against Candida albicans biofilms(2014)
Authors: Nicolas Delattin, Katrijn De Brucker, Katleen Vandamme, Arnaud Marchand, Patrick Chaltin, Bruno Cammue, Karin Thevissen
Pages: 1035 - 1044 - Identification of novel FLT3 kinase inhibitors(2013)
Authors: Amuri Kilonda, Patrick Chaltin, Arnaud Marchand, Jan Cools
Pages: 713 - 21 - Small molecule inhibitors of the LEDGF/p75 binding site of integrase (LEDGINs) block HIV replication and modulate integrase multimerization(2012)
Authors: Frauke Christ, Jonas Demeulemeester, Belete Ayele Desimmie, Arnaud Marchand, Wim Smets, Patrick Chaltin, Zeger Debyser
Pages: 4365 - 4374 - Identification and Characterization of MEL-3, a Novel AR Antagonist That Suppresses Prostate Cancer Cell Growth(2012)
Authors: Christine Helsen, Arnaud Marchand, Patrick Chaltin, Sebastian Munck, Arnout Voet, Mieke Verstuyf, Frank Claessens
Pages: 1257 - 1268 - Identification of fungicidal 2,6-disubstituted quinolines with Candida antibiofilm activity(2012)
Authors: Nicolas Delattin, Dorothée Bardiot, Arnaud Marchand, Patrick Chaltin, Katrijn De Brucker, Bruno Cammue, Karin Thevissen
Pages: 12243 - 12251 - Pre-clinical evaluation of HIV replication inhibitors that target the hiv integrase-LEDGF/p75 interaction(2011)
Authors: Chris Pickford, Frauke Christ, Stephen Shaw, Kevin Whitby, Belete Ayele Desimmie, Caroline Smith-Burchnell, Scott Butler, Arnaud Marchand, Patrick Chaltin, Zeger Debyser, et al.
Pages: 26 - 27
Patents
1 - 10 of 10
- Substituted indoline derivatives as dengue viral replication inhibitors (Inventor)
- Substituted indoline derivatives as dengue viral replication inhibitors (Inventor)
- Substituted indoline derivatives as dengue viral replication inhibitors (Inventor)
- Mono- or di-substituted indole derivatives as dengue viral replication inhibitors (Inventor)
- Aryl derivatives for treating trpm3 mediated disorders (Inventor)
- Tetrahydroquinoline derivatives as inhibitors of the yap/taz-tead activation for treating cancer (Inventor)
- Heterocycle derivatives for treating trpm3 mediated disorders (Inventor)
- Viral replication inhibitors (Inventor)
- Mono- or di-substituted indole derivatives as dengue viral replication inhibitors (Inventor)
- Substituted indoline derivatives as dengue viral replication inhibitors (Inventor)